ES2971959T3 - Terlipresina para el tratamiento de la ascitis debida a cirrosis hepática administrada como una infusión continua - Google Patents

Terlipresina para el tratamiento de la ascitis debida a cirrosis hepática administrada como una infusión continua Download PDF

Info

Publication number
ES2971959T3
ES2971959T3 ES16818751T ES16818751T ES2971959T3 ES 2971959 T3 ES2971959 T3 ES 2971959T3 ES 16818751 T ES16818751 T ES 16818751T ES 16818751 T ES16818751 T ES 16818751T ES 2971959 T3 ES2971959 T3 ES 2971959T3
Authority
ES
Spain
Prior art keywords
terlipressin
ascites
salt
patient
continuous infusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16818751T
Other languages
English (en)
Spanish (es)
Inventor
Paolo Angeli
Penelope Markham
Jonathan Adams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovie Inc
Original Assignee
Biovie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57609113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2971959(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovie Inc filed Critical Biovie Inc
Application granted granted Critical
Publication of ES2971959T3 publication Critical patent/ES2971959T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
ES16818751T 2015-06-30 2016-06-30 Terlipresina para el tratamiento de la ascitis debida a cirrosis hepática administrada como una infusión continua Active ES2971959T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562186638P 2015-06-30 2015-06-30
US201562267510P 2015-12-15 2015-12-15
US201662321558P 2016-04-12 2016-04-12
PCT/US2016/040284 WO2017004317A1 (en) 2015-06-30 2016-06-30 Treatment of ascites

Publications (1)

Publication Number Publication Date
ES2971959T3 true ES2971959T3 (es) 2024-06-10

Family

ID=57609113

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16818751T Active ES2971959T3 (es) 2015-06-30 2016-06-30 Terlipresina para el tratamiento de la ascitis debida a cirrosis hepática administrada como una infusión continua

Country Status (7)

Country Link
US (6) US9655945B2 (enExample)
EP (2) EP3347032B1 (enExample)
JP (6) JP2017014206A (enExample)
CN (2) CN120324576A (enExample)
ES (1) ES2971959T3 (enExample)
HK (1) HK1258611A1 (enExample)
WO (1) WO2017004317A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101814186B1 (ko) 2008-09-17 2018-03-14 키아스마 인코포레이티드 약제학적 조성물 및 연관된 투여방법
EP3981420A1 (en) 2014-10-24 2022-04-13 Mallinckrodt Pharmaceuticals Ireland Limited Method of treating patients with hepatorenal syndrome type 1
ES3029566T3 (en) 2015-02-03 2025-06-24 Amryt Endo Inc Treating acromegaly with oral octreotide
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療
MA46586A (fr) 2016-10-21 2019-08-28 Chiasma Inc Compositions de terlipressine et leurs procédés d'utilisation
CN112704727B (zh) * 2021-01-12 2023-05-16 重庆医科大学附属第二医院 特利加压素在制备动力性肠梗阻药物中的应用
CN113077888A (zh) * 2021-03-30 2021-07-06 福州宜星大数据产业投资有限公司 自动化meld评分方法、终端及存储介质
US20230241156A1 (en) * 2022-02-03 2023-08-03 Biovie Inc. Methods of treating disease with terlipressin

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188443A1 (en) * 2000-09-15 2002-03-20 Ferring BV Improved protocol for paracentesis
HUE027174T2 (en) * 2006-02-13 2016-10-28 Ferring Bv Use of peptide agonists of the vasopressin receptor
EP2175874A2 (en) * 2007-08-14 2010-04-21 Ferring B.V. Use of peptidic vasopressin receptor agonists
WO2009045309A2 (en) * 2007-09-28 2009-04-09 Ferring B.V. Use of v2 receptor antagonists in combination with vasopressinergic agonists
BRPI0819434A2 (pt) * 2007-11-08 2019-09-24 Univ Utah Res Found método de tratamento ou prevenção de doenças hepáticas e uso de antagonistas á angiogênese em condições de proliferação venosa anormal
WO2010023195A2 (en) 2008-08-26 2010-03-04 Kyon Biotech Ag Compositions and methods for treating cancer
DK2406399T3 (en) * 2009-03-09 2018-03-12 Bioatla Llc MIRAC PROTEINS
KR101715008B1 (ko) * 2009-06-08 2017-03-22 유씨엘 비즈니스 피엘씨 Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복
KR20130026504A (ko) * 2010-07-14 2013-03-13 큠버랜드 에멀징 테크놀로지스 아이앤씨 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법
WO2013106072A1 (en) 2012-01-10 2013-07-18 Sorbent Therapeutics, Inc. Compositions comprising crosslinked cation-binding polymers and uses thereof
JO3109B1 (ar) 2012-05-10 2017-09-20 Ferring Bv منبهات لمستقبلات v1a
CN102731625B (zh) * 2012-06-27 2014-10-15 深圳翰宇药业股份有限公司 一种纯化特利加压素的方法
CN105452857B (zh) 2012-11-12 2019-06-28 科罗拉多州立大学董事会法人团体 评价慢性肝病的疾病严重性指标
EP2988770A4 (en) * 2013-04-26 2016-12-14 La Jolla Pharma Co COMPOSITIONS AND METHOD FOR TREATING KIDNEY FAILURES
US20150056194A1 (en) 2013-08-21 2015-02-26 Georgia Regents Research Institute, Inc. Modified green tea polyphenols and methods thereof for treating liver disease
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療

Also Published As

Publication number Publication date
CN106999539A (zh) 2017-08-01
JP2022136104A (ja) 2022-09-15
US20190365848A1 (en) 2019-12-05
US20180000887A1 (en) 2018-01-04
EP3347032B1 (en) 2023-11-29
US11364277B2 (en) 2022-06-21
US20250312410A1 (en) 2025-10-09
HK1258611A1 (zh) 2019-11-15
EP3347032A4 (en) 2019-06-19
JP2025143324A (ja) 2025-10-01
JP2020172520A (ja) 2020-10-22
US20170000844A1 (en) 2017-01-05
EP4338795A2 (en) 2024-03-20
JP2023160839A (ja) 2023-11-02
US20230146264A1 (en) 2023-05-11
US9655945B2 (en) 2017-05-23
JP2018172440A (ja) 2018-11-08
EP4338795A3 (en) 2024-08-28
JP2017014206A (ja) 2017-01-19
EP3347032A1 (en) 2018-07-18
WO2017004317A1 (en) 2017-01-05
US20240165193A1 (en) 2024-05-23
CN120324576A (zh) 2025-07-18

Similar Documents

Publication Publication Date Title
ES2971959T3 (es) Terlipresina para el tratamiento de la ascitis debida a cirrosis hepática administrada como una infusión continua
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
JP2012144512A (ja) 脳腫瘍を治療するための医薬組成物又は脳腫瘍細胞のテモゾロミド耐性を低減させるための医薬組成物、及びその使用
JP2018513188A5 (enExample)
ES2922551T3 (es) Tratamiento de pacientes con diabetes mellitus tipo 2
CN107519159A (zh) 复方组合物
RU2020134307A (ru) Режимы дозирования мелфлуфена для раковых заболеваний
JP2018531605A5 (enExample)
JP2019533660A5 (enExample)
JP2020510043A5 (enExample)
JP5177785B2 (ja) 周術期患者用薬剤
TW202203946A (zh) 用於人或動物之慢性或急性之病毒感染症及/或敗血症之預防或治療的組成物
CN110891574B (zh) 用于预防和/或治疗肝细胞癌的美格列明
JP2018104291A (ja) マグネシウム化合物を有効成分として含有することを特徴とする医薬組成物
WO2016139740A1 (ja) 肝線維化改善剤
Wang et al. The use of barbiturate coma as salvage therapy in a postoperative Jehovah's Witness patient with life-threatening anemia
RU2505302C1 (ru) Лекарственное средство "поликатан"
FI4065134T3 (fi) Rautasuksinaatin antaminen suun kautta käytettäväksi raudanpuutoksen hoidossa potilailla, joilla on sydämen vajaatoiminta
CN116270674A (zh) 曼那斯汀减轻奥沙利铂毒副作用的应用
JP2021161105A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物
JP2006518722A (ja) 膵臓癌、軟部組織の肉腫、精巣腫瘍、リンパ腫、胸腺腫、ウィルムス腫瘍、腎臓癌、黒色腫、肺腫瘍、脳内転移、頭頸部の腫瘍、および乳癌の処置のための、１−（２−クロロエチル）−１−ニトロソ−３−（２−ヒドロキシエチル）ウレアの使用方法
PT1875918E (pt) Nova utilização de cloreto de amónio para a terapia de insuficiência e necrose hepática total ou parcial
JP2018104292A (ja) マグネシウム化合物を有効成分とする医薬組成物
Bruder Nausea, vomiting, pain and itching at the nape of the neck, arthralgia and leukopenia: 2 case reports
CN101297801A (zh) 5-羟基甲基糠醛的医药用途